Extracellular Vesicles in Ovarian Cancer: From Chemoresistance Mediators to Therapeutic Vectors DOI Creative Commons
Muttiah Barathan,

Nur Dina Muhammad Fuad,

Faizul Jaafar

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1806 - 1806

Published: Aug. 9, 2024

Ovarian cancer (OC) remains the deadliest gynecological malignancy, with alarming projections indicating a 42% increase in new cases and 51% rise mortality by 2040. This review explores challenges OC treatment, focusing on chemoresistance mechanisms potential of extracellular vesicles (EVs) as drug delivery agents. Despite advancements treatment strategies, including cytoreductive surgery, platinum-based chemotherapy, targeted therapies, high recurrence rate underscores need for innovative approaches. Key resistance include efflux, apoptosis disruption, enhanced DNA repair, stem cells, immune evasion, complex tumor microenvironment. Cancer-associated fibroblasts play crucial roles modulating microenvironment facilitating chemoresistance. EVs, naturally occurring nanovesicles, emerge promising carriers due to their low toxicity, biocompatibility, inherent targeting capabilities. They have shown delivering chemotherapeutics like doxorubicin, cisplatin, paclitaxel, well natural compounds such curcumin berry anthocyanidins, enhancing therapeutic efficacy while reducing systemic toxicity models. However, production yields, heterogeneity, rapid clearance, inefficient loading methods be addressed clinical application. Ongoing research aims optimize EV production, efficiency, targeting, paving way novel more effective strategies treatment. Overcoming these obstacles is unlocking full EV-based therapies improving outcomes patients.

Language: Английский

Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications DOI Creative Commons
Inseong Jung, Sanghee Shin, Moon‐Chang Baek

et al.

Experimental & Molecular Medicine, Journal Year: 2024, Volume and Issue: 56(1), P. 19 - 31

Published: Jan. 4, 2024

Abstract Cancer immunotherapy has revolutionized the approach to cancer treatment of malignant tumors by harnessing body’s immune system selectively target cells. Despite remarkable advances, there are still challenges in achieving successful clinical responses. Recent evidence suggests that cell-derived exosomes modulate generate effective antitumor responses, making them a cutting-edge therapeutic strategy. However, natural limited application due their low drug delivery efficiency and insufficient capacity. Technological advancements have allowed exosome modifications magnify intrinsic functions, load different cargoes, preferentially tumor sites. These engineered exert potent effects great potential for immunotherapy. In this review, we describe ingenious modification strategies attain desired performance. Moreover, systematically summarize tumor-controlling properties innate adaptive immunity. Collectively, review provides comprehensive intuitive guide modified exosome-based approaches, offering valuable enhance optimize

Language: Английский

Citations

46
Recent advances and clinical translation of liposomal delivery systems in cancer therapy DOI Creative Commons
Jiayi Chen,

Siyuan Hu,

Man Sun

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 193, P. 106688 - 106688

Published: Jan. 1, 2024

The limitations of conventional cancer treatment are driving the emergence and development nanomedicines. Research in liposomal nanomedicine for therapy is rapidly increasing, opening up new horizons treatment. Liposomal nanomedicine, which focuses on targeted drug delivery to improve therapeutic effect while reducing damage normal tissues cells, has great potential field therapy. This review aims clarify advantages systems We describe recent understanding spatiotemporal fate liposomes organism after different routes administration. Meanwhile, various types liposome-based that exert their respective side effects were discussed. Moreover, combination agents with other therapies (such as photodynamic photothermal therapy) demonstrated enhanced tumor-targeting efficiency efficacy. Finally, opportunities challenges faced by liposome nanoformulations entering clinical highlighted.

Language: Английский

Citations

45
Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application DOI Creative Commons
Qian Yang, Shisheng Li,

Haibo Ou

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 28, 2024

Malignancy is a major public health problem and among the leading lethal diseases worldwide. Although current tumor treatment methods have therapeutic effect to certain extent, they still some shortcomings such as poor water solubility, short half-life, local systemic toxicity. Therefore, how deliver agent so realize safe effective anti-tumor therapy become urgently be solved in this field. As medium of information exchange material transport between cells, exosomes are considered promising drug delivery carrier due their nano-size, good biocompatibility, natural targeting, easy modification. In review, we summarize recent advances isolation, identification, loading, modification carriers for alongside application therapy. Basic knowledge exosomes, biogenesis, sources, characterization methods, also introduced herein. addition, challenges related use vehicles discussed, along with future trends. This review provides scientific basis exosome systems oncological

Language: Английский

Citations

42
Exosomal circRNAs: Novel biomarkers and therapeutic targets for urinary tumors DOI
Qiang Liu, Shenglong Li

Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216759 - 216759

Published: Feb. 28, 2024

Language: Английский

Citations

22
Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies DOI Creative Commons

Amirata Mohseni,

Fatemeh Salehi,

Samaneh Rostami

et al.

Stem Cell Research & Therapy, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 7, 2025

Exosomes are small extracellular vesicles of endocytic origin released by various cell types. They consist lipid bilayers containing macromolecules such as lipids, proteins, microRNAs, growth factors, cytokines, and carbohydrates. play a critical role in the diagnosis treatment diseases. For instance, exosome contents have been utilized biomarkers body fluids (urine, saliva, serum) to identify cancers, autoimmune diseases, inflammatory conditions sepsis. Due their size ability reach tumor microenvironments, exosomes also used carriers for chemotherapeutic drugs drug delivery systems. Furthermore, evidence indicates that malignant cells release into microenvironment, influencing immune paracrine manner. Additionally, cell-derived exosomes, those from Natural Killer (NK) or cytotoxic T lymphocytes (CTLs), show potential therapeutic agents treating malignancies like leukemia. This review discusses diagnostic hematological explores these

Language: Английский

Citations

3
Delving Into Nanoparticle Systems for Enhanced Drug Delivery Technologies DOI

Nimra Abaidullah,

Khalid Muhammad, Yasir Waheed

et al.

AAPS PharmSciTech, Journal Year: 2025, Volume and Issue: 26(3)

Published: March 4, 2025

Language: Английский

Citations

2
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies DOI Creative Commons
Shan Muhammad, Tao Fan,

Yang Hai

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: July 29, 2023

Abstract Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function expression the tumor microenvironment make them attractive targets for immunotherapy, leading to development of IL-2/IL-2R-targeted therapeutic strategies. However, dynamic interplay between IL-2/IL-2R various cells their dual roles promoting activation tolerance presents a complex landscape clinical exploitation. This review discusses pivotal IL-2 IL-2R tumorigenesis, shedding light on potential as diagnostic prognostic markers manipulation cancer. It underlines necessity balance anti-tumor activity with regulatory T-cell expansion evaluates strategies such dose optimization selective targeting enhanced effectiveness. The article explores recent advancements field, including developing genetically engineered variants, combining therapies other cancer treatments, benefits multidimensional approach integrating molecular profiling, immunological analyses, data. concludes that deeper understanding interactions within is crucial realizing full IL-2-based therapies, heralding promise improved outcomes patients.

Language: Английский

Citations

41
Exosomes in brain diseases: Pathogenesis and therapeutic targets DOI Creative Commons
Qingying Si, Linlin Wu,

Deshui Pang

et al.

MedComm, Journal Year: 2023, Volume and Issue: 4(3)

Published: June 1, 2023

Exosomes are extracellular vesicles with diameters of about 100 nm that naturally secreted by cells into body fluids. They derived from endosomes and wrapped in lipid membranes. involved intracellular metabolism intercellular communication. contain nucleic acids, proteins, lipids, metabolites the cell microenvironment cytoplasm. The contents exosomes can reflect their cells' origin allow observation tissue changes states under disease conditions. Naturally have specific biomolecules act as "fingerprint" parent cells, changed pathological conditions be used biomarkers for diagnosis. low immunogenicity, small size, cross blood-brain barrier. These characteristics make unique engineering carriers. incorporate therapeutic drugs achieve targeted drug delivery. carriers therapy still infancy, but exosome provides a new perspective cell-free therapy. This review discussed relationship occurrence treatment some neuropsychiatric diseases. In addition, future applications diagnosis disorders were evaluated this review.

Language: Английский

Citations

31
Digging the intercellular crosstalk via extracellular vesicles: May exosomes be the drug delivery solution for target glioblastoma? DOI Creative Commons
Ana Helena MAcedo-Pereira, Cláudia Martins, Jorge Lima

et al.

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 358, P. 98 - 115

Published: April 29, 2023

Glioblastoma (GBM) is an adult's most aggressive brain tumor. The advances in molecular pathology and cell signaling pathways have deepened researchers' understanding of intercellular communication mechanisms that can induce tumor progression, namely the release extracellular vesicles. Exosomes are small vesicles various biological fluids released by almost all cells, thus carrying biomolecules specific to their parental cell. Several pieces evidence indicate exosomes mediate microenvironment cross blood-brain barrier (BBB), valuable tools for diagnostic therapeutic applications under scope diseases such as tumors. This review aims resume several characteristics interplay between glioblastoma exosomes, describing highlight studies demonstrate role GBM potential non-invasive diagnoses approaches, namely, nanocarriers drug or gene delivery cancer vaccines.

Language: Английский

Citations

27
Extracellular Vesicles: A New Star for Gene Drug Delivery DOI Creative Commons

Man Sun,

Huan Zhang, Jiayi Liu

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 2241 - 2264

Published: March 1, 2024

Abstract: Recently, gene therapy has become a subject of considerable research and been widely evaluated in various disease models. Though it is considered as stand-alone agent for COVID-19 vaccination, still suffering from the following drawbacks during its translation bench to bedside: high sensitivity exogenous nucleic acids enzymatic degradation; severe side effects induced either by or components formulation; difficulty cross barriers before reaching therapeutic target. Therefore, successful application therapy, safe reliable transport vector urgently needed. Extracellular vesicles (EVs) are ideal candidate delivery drugs owing their low immunogenicity, good biocompatibility toxicity. To better understand properties EVs advantages drug vehicles, this review covers origin methods generation, well common isolation purification research, with pros cons discussed. Meanwhile, engineering also highlighted. In addition, paper presents progress EVs-mediated microRNAs, small interfering RNAs, messenger plasmids, antisense oligonucleotides. We believe will provide theoretical basis development drugs. Keywords: extracellular vesicles, system,

Language: Английский

Citations

12